Balaji Virassamy

2.6k total citations · 1 hit paper
12 papers, 946 citations indexed

About

Balaji Virassamy is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Balaji Virassamy has authored 12 papers receiving a total of 946 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Balaji Virassamy's work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (5 papers) and Immune Cell Function and Interaction (3 papers). Balaji Virassamy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (5 papers) and Immune Cell Function and Interaction (3 papers). Balaji Virassamy collaborates with scholars based in Australia, Belgium and France. Balaji Virassamy's co-authors include Sherene Loi, Peter Savas, Stephen J. Luen, Roberto Salgado, Laura K. Mackay, Paul J. Neeson, Paul A. Beavis, Sneha Sant, Ann Byrne and Ran Li and has published in prestigious journals such as Nature Communications, Nature reviews. Cancer and PLoS ONE.

In The Last Decade

Balaji Virassamy

12 papers receiving 939 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Towards targeting the breast cancer immune microenvironment

2024 119 citations Michael A. Harris, Peter Savas et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Balaji Virassamy Australia	10	652	360	246	231	174	12	946
Nomathamsanqa Resegofetse Maimela China	9	491 0.8×	475 1.3×	143 0.6×	298 1.3×	150 0.9×	12	901
Marcelo Cruz United States	7	593 0.9×	243 0.7×	286 1.2×	300 1.3×	216 1.2×	8	913
Zhi L. Teo Australia	13	718 1.1×	470 1.3×	214 0.9×	415 1.8×	275 1.6×	18	1.2k
Yacine Barèche Belgium	14	600 0.9×	249 0.7×	197 0.8×	321 1.4×	356 2.0×	24	1.0k
Xiubao Ren China	16	685 1.1×	358 1.0×	143 0.6×	378 1.6×	216 1.2×	42	1.0k
María Gato Spain	16	848 1.3×	766 2.1×	147 0.6×	306 1.3×	116 0.7×	23	1.3k
Sofia Sousa France	10	399 0.6×	355 1.0×	132 0.5×	326 1.4×	138 0.8×	15	843
Sayali Onkar United States	8	539 0.8×	497 1.4×	149 0.6×	382 1.7×	208 1.2×	11	989
Anaïs Boisson Belgium	12	656 1.0×	510 1.4×	129 0.5×	183 0.8×	105 0.6×	21	896

Countries citing papers authored by Balaji Virassamy

Since Specialization

Citations

This map shows the geographic impact of Balaji Virassamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Balaji Virassamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Balaji Virassamy more than expected).

Fields of papers citing papers by Balaji Virassamy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Balaji Virassamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Balaji Virassamy. The network helps show where Balaji Virassamy may publish in the future.

Co-authorship network of co-authors of Balaji Virassamy

This figure shows the co-authorship network connecting the top 25 collaborators of Balaji Virassamy. A scholar is included among the top collaborators of Balaji Virassamy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Balaji Virassamy. Balaji Virassamy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Virassamy, Balaji, Stephen J. Luen, Peter Savas, et al.. (2024). Sustained lymphocyte decreases after treatment for early breast cancer. npj Breast Cancer. 10(1). 94–94. 2 indexed citations

Harris, Michael A., et al.. (2024). The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. Trends in cancer. 10(6). 490–506. 18 indexed citations

Harris, Michael A., Peter Savas, Balaji Virassamy, et al.. (2024). Towards targeting the breast cancer immune microenvironment. Nature reviews. Cancer. 24(8). 554–577. 119 indexed citations breakdown →

Teo, Zhi L., Mark J. O’Connor, Christopher Mintoff, et al.. (2023). Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. npj Breast Cancer. 9(1). 68–68. 14 indexed citations

Li, Ran, Sneha Sant, Franco Caramia, et al.. (2023). Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer. JNCI Journal of the National Cancer Institute. 115(7). 805–814. 9 indexed citations

Byrne, Ann, Peter Savas, Sneha Sant, et al.. (2020). Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology. 17(6). 341–348. 211 indexed citations

Teo, Zhi L., Sathana Dushyanthen, Franco Caramia, et al.. (2017). Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research. 77(22). 6340–6352. 148 indexed citations

Dushyanthen, Sathana, Zhi L. Teo, Franco Caramia, et al.. (2017). Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications. 8(1). 606–606. 96 indexed citations

Wein, Lironne, Peter Savas, Stephen J. Luen, et al.. (2017). Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Frontiers in Oncology. 7. 156–156. 86 indexed citations

10.

Luen, Stephen J., Balaji Virassamy, Peter Savas, Roberto Salgado, & Sherene Loi. (2016). The genomic landscape of breast cancer and its interaction with host immunity. The Breast. 29. 241–250. 194 indexed citations

11.

Deo, Shivashni, Balaji Virassamy, Catriona Halliday, et al.. (2015). Stimulation with lysates of Aspergillus terreus, Candida krusei and Rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. Cytotherapy. 18(1). 65–79. 18 indexed citations

12.

Yang, Miao, Balaji Virassamy, Swarna Lekha Vijayaraj, et al.. (2013). The Intracellular Domain of Sortilin Interacts with Amyloid Precursor Protein and Regulates Its Lysosomal and Lipid Raft Trafficking. PLoS ONE. 8(5). e63049–e63049. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact